-
Mashup Score: 0Making cancer research more inclusive - 3 year(s) ago
Based on a virtual discussion during the American Association for Cancer Research (AACR) 2020 Annual Meeting, we asked several scientists actively working to improve representation of Black American populations in cancer research how they are addressing these issues.
Source: Nature Reviews CancerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Dr. Alan Lyss reviews data showing how artificial intelligence can help physicians diagnose and treat cancer.
Source: www.mdedge.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Using AI to make highly personalized treatments for advanced cancers. https://t.co/VJN7FiXYWt #AACR2020 @HeartlandOncDoc https://t.co/jE4drOe41H
-
-
Mashup Score: 0
Dr. Alan Lyss reviews data showing how artificial intelligence can help physicians diagnose and treat cancer.
Source: www.mdedge.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Using AI to make highly personalized treatments for advanced cancers. https://t.co/Iki3KiBJLq #AACR2020 @HeartlandOncDoc https://t.co/1vrba23UOH
-
-
Mashup Score: 3Andrew Zhu on Atezolizumab/Bevacizumab in HCC - The ASCO Post - 4 year(s) ago
AACR Virtual Annual Meeting 2020 Andrew X. Zhu, MD, PhD, of Massachusetts General Hospital, discusses an exploratory analysis seeking to identify tumor-based molecular biomarkers that may be associated with clinical response or resistance to the combination treatment of atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma…
Source: www.ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Andrew X. Zhu, MD, PhD, on Hepatocellular Carcinoma: Atezolizumab Combined With Bevacizumab https://t.co/HMmoQTlzxg #hpbcsm #AACR20 #AACR2020 #oncology #cancer @MassachusettsG2 https://t.co/SOmBVeqdg8
-
-
Mashup Score: 0ctDNA May Be a Prognostic Biomarker of Disease Recurrence in Patients With Lung Cancer - The ASCO Post - 4 year(s) ago
By Jo Cavallo Posted: 4/27/2020 1:24:00 PM Last Updated: 4/27/2020 3:04:49 PM The TRACERx study investigated phylogenetic tracking and minimal residual disease (MRD) detection using circulating tumor DNA (ctDNA) profiling following resection in patients with stage I to III…
Source: www.ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ctDNA May Be a Prognostic Biomarker of Disease Recurrence in Patients With Lung Cancer https://t.co/RObFyyZank #LCSM #oncology #cancer #AACR20 #AACR2020 #biomarkers
-
-
Mashup Score: 2
By The ASCO Post Staff Posted: 4/27/2020 12:42:00 PM Last Updated: 4/27/2020 4:43:47 PM New data from the phase III EMBRACA trial showed the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib did not produce a statistically significant overall survival benefit for…
Source: www.ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Final Overall Survival Results From the Phase III EMBRACA Trial https://t.co/eTPyasm3hd #AACR2020 #AACR20 #bcsm #oncology #cancer
-
-
Mashup Score: 0
Dr. Alan Lyss reviews data showing how artificial intelligence can help physicians diagnose and treat cancer.
Source: www.mdedge.comCategories: General Medicine News, Latest HeadlinesTweet-
Using AI to make highly personalized treatments for advanced cancers. https://t.co/WYIv3Y41y6 #AACR2020 @HeartlandOncDoc https://t.co/0Dt96UnWON
-
-
Mashup Score: 3No Increase in Risk of Death From COVID-19 in Cancer Patients - 4 year(s) ago
Immune checkpoint inhibition was not associated with an increased mortality risk from COVID-19 in patients with cancer.
Source: MedscapeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
"Treatment with immune checkpoint inhibition does not seem to pose an additional mortality risk for cancer patients with #COVID19.” https://t.co/uyTBo3412b #AACR2020
-
-
Mashup Score: 14No Increase in Risk of Death From COVID-19 in Cancer Patients - 4 year(s) ago
Immune checkpoint inhibition was not associated with an increased mortality risk from COVID-19 in patients with cancer.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
"Treatment with immune checkpoint inhibition does not seem to pose an additional mortality risk for cancer patients with #COVID19.” https://t.co/qYhYpwsBUG #AACR2020
-
-
Mashup Score: 1How aging affects melanoma development and treatment response - 4 year(s) ago
Dr. Alan P. Lyss reviews research into how the aging microenvironment affects tumor cell metabolism, angiogenesis, and treatment resistance in melanoma.
Source: www.mdedge.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
How the aging microenvironment affects tumor cell metabolism, #angiogenesis, and treatment resistance in #melanoma. via @heartlandOncDoc #melsm #AACR20 #AACR2020 https://t.co/eguSUQxTK3 https://t.co/IPhNEY2FhP
-
NEW Viewpoint! Based on discussions during the #AACR2020, we asked J. D. Carpten, L. Fashoyin-Aje @LolaFashoyinAje, L. A. Garraway & R. Winn about their work to make cancer research more inclusive. https://t.co/KAm1qDglaO @NatresCancer @FDAOncology https://t.co/BaytHkiXwx